[ad_1]
AI-backed distant monitoring and digital therapeutics firm Biofourmis added one other $20 million to its Sequence D spherical, bringing its increase to $320 million.
The extension funding comes from Intel Capital, the strategic funding division of chipmaker Intel. The corporate first introduced its Series D in April, which boosted Biofourmis to unicorn standing with a valuation of $1.3 billion.
Biofourmis additionally introduced it had appointed two new board members: former Tenet Healthcare Chairman and CEO Trevor Fetter and Sachin H. Jain, president and CEO of SCAN Group and SCAN Well being Plan.
“To obtain this extra funding from the enterprise capital arm of a world know-how large throughout an unpredictable time in digital well being funding is additional validation of Biofourmis’ market energy and potential and validates that we’re distinguishing ourselves available in the market,” Biofourmis founder and CEO Kuldeep Singh Rajput mentioned in an announcement. “We’re on a robust trajectory for continued strategic development within the coming years by way of prospects, companions and resolution improvement.”
Affected person monitoring firm Sibel Health scored $33 million final week in a Sequence B funding spherical led by the Steele Basis for Hope.
The Northwestern College spinout will use the funds to deploy its ANNE One platform for in-home and hospital monitoring. The system, which incorporates two varieties of wearable sensors and an analytics app, received FDA 510(k) clearance final yr.
Sibel mentioned the Sequence B brings its whole increase to greater than $50 million. The corporate additionally introduced it had appointed Jon Otterstatter, former CEO and cofounder of cardiac monitoring firm Preventice, chairman of the board. Matthew Banet joins the corporate as president from Baxter Worldwide.
“What makes us distinctive as a digital well being firm is that our product is vertically built-in — we consider that all the things issues, from the adhesive we place on the pores and skin to how the sensor matches on the physique to the ultimate alert a clinician sees for medical decision-making,” Dr. Steve Xu, Sibel CEO and cofounder, mentioned in an announcement. “We’re proud that our know-how will be doubtlessly deployed in each the neonatal intensive care unit and within the house for distant affected person monitoring.”
Atropos Well being, which makes an app that helps physicians entry real-world proof to information affected person care, introduced it had raised $14 million in Sequence A funding.
The spherical was led by Breyer Capital with participation from buyers together with Emerson Collective and Boston Millennia Companions. The corporate’s device permits suppliers to obtain studies primarily based on previous affected person encounters that may assist reply medical questions the place there is not a transparent care path primarily based on established analysis.
Atropos plans to make use of the funds to rent for its business group and develop its oncology product. The startup additionally introduced it had appointed cofounder Brigham Hyde as CEO.
“I’m excited in regards to the monumental potential Atropos has to advance how evidence-based drugs is practiced throughout the globe,” Hyde mentioned in an announcement. “I’m honored to get the possibility to guide the enterprise day-to-day and convey customized real-world proof to sufferers and caregivers in all places.”
[ad_2]
Source link